TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910661

Intervention type: OTHER
Intervention: Focus Group
Description: Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.

Intervention type: OTHER
Intervention: Focus Group
Description: Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.

Intervention type: OTHER
Intervention: Focus Group
Description: Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
Study: NCT00979784

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Better Weight
Description: Standard cognitive behavioral treatment focused on dietary \& exercise behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Weight & Better Sleep
Description: Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
Study: NCT02253303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: midline incision or off-midline incision
Description: Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: midline incision or off-midline incision
Description: Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
Study: NCT02316366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astoflo Plus fluid warmer
Description: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
Study: NCT04417374

Intervention type: OTHER
Intervention: Description of groups caracteristics
Description: Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.

Intervention type: OTHER
Intervention: Description of groups caracteristics
Description: Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
Study: NCT01702597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)
Description: Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will receive a standardized physical therapy.
Study: NCT03252951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isometric Training
Description: Different Anal Sphincter Exercise Types for muscle hypertrophy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Standard of Care Biofeedback Training
Study: NCT02145689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
Study: NCT04571866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-glucan bread
Description: Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Beta-glucan bread
Description: Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
Study: NCT04223869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed
Study: NCT00548054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent killed oral cholera vaccine
Description: Oral, 1.5 ml, given 2 times at least 14 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent killed oral cholera vaccine
Description: Oral, 1.5 ml, given 2 times at least 14 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent killed oral cholera vaccine
Description: Oral, 1.5 ml, given 2 times at least 14 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Killed Escherichia coli K12 placebo
Description: oral, 1.5 ml per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Killed Escherichia coli K12 placebo
Description: oral, 1.5 ml per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Killed Escherichia coli K12 placebo
Description: oral, 1.5 ml per dose
Study: NCT04334434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: 15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
Study: NCT02168842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isradipine
Description: Oral capsules Isradipine IR, up to 10 mg, taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Isradipine)
Description: Sugar Pill manufactured to look like Isradipine but has no active ingredients
Study: NCT02547233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT00975351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C5-labelled 5-methyltetrahydrofolic acid
Description: one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention.
Study: NCT02262923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Study: NCT04327492

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP
Description: peak wave velocity; gray weale plaque classification
Study: NCT00638131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bosentan
Description: 62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
Study: NCT00551460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study: NCT01890304

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
Study: NCT02489903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT02587468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus+(R)
Description: before-after comparison of plasma phenolics
Study: NCT00133146

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grass MATA MPL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL
Study: NCT01272804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319
Description: Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
Study: NCT00885651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolole (Selo-Zok ®)
Description: Tablets, 200 mg, once a day, 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolole (Selo-Zok ®)
Description: Tablets, 200 mg, once a day, 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02803892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
Study: NCT03155256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided injection of coils with cyanoacrylate
Description: First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided injection of coils
Description: First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
Study: NCT02656160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 3 hrs before sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine
Description: Dalfampridine 10 mg extended release 3 hrs before sleep
Study: NCT00473135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN1delta30
Study: NCT03411460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre™ system
Description: Measured non-invasively via scanner

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finger prick
Description: Blood test
Study: NCT02444481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polygynax combinaison of polymyxin, Neomycin and Nystatin
Study: NCT00714597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study: NCT00400985

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.
Description: SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
Study: NCT02274194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oronasal CPAP
Description: use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
Study: NCT02472769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBP-9414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water
Study: NCT02142660

Intervention type: PROCEDURE
Intervention: ablation of gastric
Description: Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
Study: NCT03421093

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries or surgeries plus adjuvant therapies
Study: NCT02262143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg, qd, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg, qd, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 160mg, qd, po
Study: NCT03524300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
Study: NCT00512304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: association chemotherapy and radiochemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: association chemotherapy and radiochemotherapy
Study: NCT02498496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 100 mL of Normal Saline
Study: NCT02317081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axetis Inert Coronary Stents
Description: de novo coronary artery stenosis in native vessels
Study: NCT03024853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PAST

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PRESENT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS FUTURE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Study: NCT00394953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed, iv.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv / month, starting dose
Study: NCT04501913

Intervention type: PROCEDURE
Intervention: Patient Monitoring
Description: Undergo remote perioperative telemonitoring

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04250987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath(R)
Description: IC SpeediCath ® connected to pressure sensor
Study: NCT02335125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Elements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic Drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Management
Study: NCT04371861

Intervention type: DEVICE
Intervention: Peripheral Artery Treatment
Description: Peripheral lesions may be treated by any standard of care methods of treatment.
Study: NCT05666388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue stenting
Description: Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
Study: NCT01849666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: 6 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg bid orally
Study: NCT03601533

Intervention type: DRUG
Group type: OTHER
Intervention: Phenol
Description: 1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
Study: NCT02171325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Study: NCT04626895

Intervention type: DEVICE
Group type: OTHER
Intervention: Paxman Scalp Cooling Device
Description: Paxman scalp cooling device
Study: NCT01071525

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Niacin\Laropiprant
Description: Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin\Laropiprant
Description: Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant